Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | c/o 1200 - 750 West Pender Street Vancouver BC V6C 2T8 |
Tel: | N/A |
Website: | https://www.alphacognition.com |
IR: | See website |
Key People | ||
Michael Mcfadden Chief Executive Officer, Director | Donald A. Kalkofen Chief Financial Officer | Lauren D'Angelo Chief Commercial Officer |
Business Overview |
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company's ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. |
Financial Overview |
For the three months ended 31 March 2024, Alpha Cognition Inc revenues was not reported. Net loss increased from $1.9M to $5M. Higher net loss reflects Consulting fees increase from $21K to $2.3M (expense), (Loss) gain on revaluation of derivative decrease from $55K (income) to $620K (expense), Professional fees increase of 36% to $376K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.02 to -$0.03. |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $110.92M as of Mar 31, 2024 |
Annual revenue (TTM): | $0.00M as of Mar 31, 2024 |
EBITDA (TTM): | -$16.68M as of Mar 31, 2024 |
Net annual income (TTM): | -$23.10M as of Mar 31, 2024 |
Free cash flow (TTM): | -$11.93M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 150,225,536 as of Apr 30, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |